XML 49 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]        
Total revenues $ 34,470 $ 36,769 $ 108,215 $ 80,253
Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 4,822 7,816 12,167 18,588
EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 5,987 4,685 14,805 17,135
APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 23,661 24,268 81,243 44,530
Product revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 28,042 28,731 93,376 53,674
Research and development revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 6,428 8,038 14,839 26,579
Performance Enzymes        
Disaggregation of Revenue [Line Items]        
Total revenues 31,146 32,584 100,774 68,397
Performance Enzymes | Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 3,654 5,999 8,514 12,573
Performance Enzymes | EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 3,831 2,317 11,017 11,294
Performance Enzymes | APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 23,661 24,268 81,243 44,530
Performance Enzymes | Product revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 28,042 28,731 93,376 53,674
Performance Enzymes | Research and development revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 3,104 3,853 7,398 14,723
Novel Biotherapeutics        
Disaggregation of Revenue [Line Items]        
Total revenues 3,324 4,185 7,441 11,856
Novel Biotherapeutics | Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 1,168 1,817 3,653 6,015
Novel Biotherapeutics | EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 2,156 2,368 3,788 5,841
Novel Biotherapeutics | APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Novel Biotherapeutics | Product revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Novel Biotherapeutics | Research and development revenue        
Disaggregation of Revenue [Line Items]        
Total revenues $ 3,324 $ 4,185 $ 7,441 $ 11,856